Abstract:Background China’s pharmaceutical market is growing at a healthy pace. This is due to potential rising per capita income, an increasing elderly population, urbanisation demographics and more access to health care. Methodology The methodology used is a comparative study on the basis of original empirical research. More specifically, the part of examination facts and regulation has been written by conducting empirical research on current international and national resource concerning the subject from books, various guidelines, rules and regulation, articles, published reports and internet. Results Generally the regulatory environment in China has been considered as an very challenging one. From regulatory perspective, CFDA regulations have not been stringent enough nor has it been robust enough to create a quality supply of medications, with (1) concerns in the subject matter, quality comparison between international regulatory standard and usually accepted local products and manufactures set standards; (2) a timeline for regulatory assessment and authorization of new drugs which is much longer in comparison to most countries; (3) less number of regulatory reviewer which has led to a backlog of earlier application. The journey to reshape China from ‘made-in-China’ to ‘discovered-in-China’ is highly challenging. (4) Complications with local protection, corruption and a lack of transparency. The directives from Government has recognized the need for significant system-level transformations for streamlining the pharmaceutical regulatory environment. Conclusion Continuing on the route of reform is promising that all Chinese citizens is eventually having access to safe, effective and high-quality medications in affordable price. These reformations are encouraging and promising not only for China’s health care system, but also for global Pharmaceutical industry and that’s the reason, now many big Pharma companies are considering China as a prime focus. The companies need to make use of the new opportunities, accessible to experience the benefit of faster time-to-market, and cause rewarding growth prospect for both domestic/ multinational companies.

Changes of Drug Sales and Marketing Model in Pharmaceutical Companies under the New Situation

Study on Strategic Transformation of Chain Drugstore 's Business Model under New Medical Reform Policy

Application of clinical model which consisted of clinician and clinical pharmacists in compliance of patients with Parkinson's disease

Marketing training strategies that pharmaceutical sales managers use to reduce unethical behavior

Drug Promotions Between Ethics, Regulations, and Financial Interests

New drug adoption models: a review and assessment of future needs

Supervision and legal control of illegal marketing in medical and health care enterprises

Exploring Ethical Issues in Pharmaceutical Marketing’s Strategies: A Critical Marketing Perspective

The Impact of Current Trends in Health Care on the Pharmaceutical Sales Force of the Future

Advertising Strategy Based on Brand Strategy in Health Care and Cosmetics Industry

Responsibility and mission of clinical pharmacists given by new medical reform

Analysis of Current Pharmaceutical Advertising Market in China

Drug consulting and administration for health-care professionals

Drug discovery and drug marketing with the critical roles of modern administration

Transformation of marketing practices on the pharmaceutical market in Russia: New challenges and opportunities

Challenges and prospects in Chinese pharmaceutical regulatory environment

Theoretic research of drug market economics

Pharmaceutical enterprises drug quality strategy Moran analysis considering government supervision and new media participation

Validating ADME QSAR Models Using Marketed Drugs

Optimization of the marketing mix in the health care industry

Refocusing on R&D model or redefining marketing strategy? Anticipating sustainability for generic pharmaceutical industry